ApoE4 Classification


ALZHEIMER’S DISEASE RISK Apolipoprotein E4 (ApoE4) gene is established as the strongest genetic risk factor for Alzheimer’s Disease (AD). Assessment of ApoE4 allele expression is a powerful tool for AD risk prediction enabling stratification of at-risk populations.


Direct determination of ApoE4 status without the need for genotyping and related genetic testing consent requirements


Plasma protein measurement with 100% concordance to genotyping methods


Enables high throughput screening in selected populations, allowing early identification of AD risk to facilitate appropriate lifestyle and therapeutic interventions


Applicable to epidemiological studies and high-risk patient recruitment to relevant clinical trials


EVIDENCE INVESTIGATOR


• Cost effective and efficient multiplex testing over other ELISA or PCR methods


• Limited sample volume and handling requirements • Assay time within 3 hours


+44 (0) 28 9442 2413 | randox.com | marketing@randox.com


Copyright © Randox Laboratories Ltd. All rights Reserved. VAT number: GB 151682708. Product availability may vary from country to country. Some products may be for Research Use Only. For more information on product application and availability, please contact your local Randox Representative


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53